CELL INTELLIGENCE · 肿瘤细胞治疗研究

阻断可溶性 TNFα 通过下调 MUC4 使 HER2 阳性乳腺癌对曲妥珠单抗敏感并逆转免疫抑制

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.

这些发现为 MUC4+和 HER2+乳腺癌患者采用 sTNFα阻断联合曲妥珠单抗或曲妥珠单抗药物偶联物以克服曲妥珠单抗耐药提供了依据。

乳腺癌管理的新策略：从治疗到长期缓解

Novel strategies in breast cancer management: From treatment to long-term remission.

HER2+乳腺癌患者接受化疗联合曲妥珠单抗联合帕妥珠单抗新辅助治疗的外周免疫特征深入分析

In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pe

以人钠碘同向转运体为基础的正电子发射断层显像对靶向 HER2 卵巢癌的 CAR-NK 细胞成像

Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.

乳腺癌患者中依据 FcεRIγ 和 NKG2C 表达的人 NK 细胞亚群在 HER2⁺ 靶向治疗中的表型与功能分析

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast

靶向人表皮生长因子受体 2 (HER2) 的嵌合抗原受体 (CAR) 用于肿瘤免疫治疗：近期进展

Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.

来自大肠杆菌的全长重组抗体：生产、表征、效应功能（Fc）工程化与临床评价

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.

靶向 ADCC：免疫治疗时代 HER2 乳腺癌的另一种策略

Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era.

CAR-T 与 CAR-NK 细胞疗法治疗卵巢癌的当前进展

Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.

装载可切换 CAR 的基因修饰 NK 细胞用于治疗 HER2 阳性肿瘤

Genetically modified NK cells equipped with a switchable CAR for the treatment of HER2-positive cancers.